Keros ends PAH program, cuts 45% of staff, expects $17M annual savings

Keros Therapeutics, Inc.

TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.
Workforce reduced ~45% to 85 employees; one-time severance charges of ~$3.2M in Q2 2025.
Annualized cost savings of ~$17M expected; restructuring substantially complete by Q4 2025.
Strategic alternatives review ongoing; preliminary update to be provided by June 9, 2025.

item 2.05item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.